Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-02 23:34 | 2025-09-02 | CYTK | CYTOKINETICS INC | Harrington Robert Arthur | Director | SELL | $48.67 | 2,150 | $104,641 | 20,493 |
| 2025-09-02 23:31 | 2025-09-02 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $48.76 | 5,000 | $243,800 | 378,108 |
| 2025-09-03 04:52 | 2025-08-25 | STTK | Shattuck Labs, Inc. | ORBIMED ADVISORS LLC | Director | BUY | $0.87 | 6,306,127 | $5,471,826 | 1,051,021 |
| 2025-08-30 00:03 | 2025-08-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $20.63 | 3,250 | $67,039 | 23,000 |
| 2025-08-29 23:02 | 2025-08-27 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bhatia Sangeeta N. | Director | SELL | $386.69 | 266 | $102,860 | 4,565 |
| 2025-08-29 23:28 | 2025-08-28 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Director, Officer | OPT+S | $49.39 | 25,000 | $1,234,700 | 305,871 |
| 2025-08-29 23:55 | 2025-08-21 | AKTX | Akari Therapeutics Plc ADR | Gaslightwala Abizer | Director, Officer | BUY | $0.93 | 21,000 | $19,541 | 298,574 |
| 2025-08-29 23:19 | 2025-08-27 | APLS | Apellis Pharmaceuticals Inc. | Francois Cedric | Director, Officer | SELL | $28.23 | 225,000 | $6,352,740 | 307,946 |
| 2025-08-29 23:09 | 2025-08-27 | AGIO | Agios Pharmaceuticals Inc. | Scadden David | Director | OPT+S | $40.00 | 200 | $8,000 | 17,603 |
| 2025-08-30 03:34 | 2025-08-27 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $13.99 | 5,029 | $70,356 | 213,304 |
| 2025-08-30 03:35 | 2025-08-27 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | Officer | SELL | $14.00 | 2,000 | $27,992 | 31,333 |
| 2025-08-30 00:30 | 2025-08-27 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Director | SELL | $59.25 | 4,000 | $237,000 | 9,130 |
| 2025-08-29 23:05 | 2025-08-27 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $45.10 | 34,800 | $1,569,431 | 1,092,633 |
| 2025-08-29 23:21 | 2025-08-19 | PGEN | PRECIGEN, INC. | AGEE NANCY H | Director | BUY | $3.79 | 26,005 | $98,642 | 202,841 |
| 2025-08-30 02:08 | 2025-08-27 | AXSM | Axsome Therapeutics, Inc. | JEFFS ROGER | Director | SELL | $121.72 | 60,000 | $7,303,398 | 70,974 |
| 2025-08-30 00:21 | 2025-08-28 | XERS | Xeris Biopharma Holdings, Inc. | SHERMAN JEFFREY W | Director | OPT+S | $7.92 | 42,232 | $334,515 | 219,188 |
| 2025-08-30 01:46 | 2025-08-22 | CYRX | Cryoport, Inc. | Hariri Robert J | Director | SELL | $8.60 | 5,000 | $43,000 | 26,275 |
| 2025-08-29 23:05 | 2025-08-27 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Director | SELL | $45.01 | 3,588 | $161,496 | 129,644 |
| 2025-08-29 00:40 | 2025-08-26 | SION | Sionna Therapeutics, Inc. | Ridloff Elena | Officer | SELL | $25.70 | 23,416 | $601,857 | 48,116 |
| 2025-08-28 23:25 | 2025-08-27 | AMRX | Amneal Pharmaceuticals Inc. | Kiely John | Director | SELL | $9.23 | 32,000 | $295,360 | 225,433 |
| 2025-08-28 23:55 | 2025-08-26 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Director, Officer | OPT+S | $14.60 | 100,000 | $1,459,760 | 23,400 |
| 2025-08-29 00:40 | 2025-08-26 | SION | Sionna Therapeutics, Inc. | Cloonan Michael | Director, Officer | OPT+S | $24.97 | 25,000 | $624,360 | 547,343 |
| 2025-08-29 02:28 | 2025-08-26 | QTTB | Q32 Bio Inc. | Violette Shelia M. | Officer | SELL | $1.80 | 2,990 | $5,385 | 58,384 |
| 2025-08-29 02:20 | 2025-08-26 | QTTB | Q32 Bio Inc. | Kalowski Lee | Officer | SELL | $1.80 | 4,240 | $7,636 | 49,010 |
| 2025-08-29 02:32 | 2025-08-26 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | Director, Officer | SELL | $1.80 | 10,494 | $18,900 | 121,506 |
| 2025-08-28 23:14 | 2025-08-28 | LLY | ELI LILLY & Co | Zakrowski Donald A | Officer | SELL | $734.93 | 1,000 | $734,930 | 3,840 |
| 2025-08-28 23:56 | 2025-08-26 | RLMD | RELMADA THERAPEUTICS, INC. | TRAVERSA SERGIO | Director, Officer | BUY | $0.67 | 265,976 | $178,098 | 1,000,000 |
| 2025-08-29 03:39 | 2025-08-26 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.79 | 4,109 | $7,358 | 1,909,625 |
| 2025-08-28 23:05 | 2025-08-27 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | Officer | SELL | $17.31 | 470 | $8,136 | 92,656 |
| 2025-08-29 02:30 | 2025-08-26 | ARDX | Ardelyx Inc. | Williams Laura A | Officer | OPT+S | $6.12 | 80,000 | $489,680 | 366,322 |
| 2025-08-29 02:29 | 2025-08-21 | ARDX | Ardelyx Inc. | Kelliher Mike | Officer | SELL | $5.93 | 5,417 | $32,132 | 276,741 |
| 2025-08-29 00:00 | 2025-08-26 | CPRX | CATALYST PHARMACEUTICALS, INC. | Miller Steve | Officer | OPT+S | $20.28 | 115,000 | $2,332,200 | 949,663 |
| 2025-08-29 00:00 | 2025-08-26 | CPRX | CATALYST PHARMACEUTICALS, INC. | Daly Richard J | Director, Officer | OPT+S | $20.62 | 22,970 | $473,641 | 226,794 |
| 2025-08-29 00:00 | 2025-08-27 | CPRX | CATALYST PHARMACEUTICALS, INC. | Tierney David S | Director | OPT+S | $20.20 | 26,000 | $525,200 | 379,620 |
| 2025-08-28 00:08 | 2025-08-25 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | Officer | SELL | $24.86 | 8,269 | $205,567 | 15,000 |
| 2025-08-27 23:30 | 2025-08-25 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $74.62 | 4,000 | $298,489 | 48,034 |
| 2025-08-28 01:44 | 2025-08-25 | OCUL | OCULAR THERAPEUTIX, INC | Kaiser Peter | Officer | SELL | $12.04 | 3,011 | $36,252 | 204,093 |
| 2025-08-28 01:43 | 2025-08-25 | OCUL | OCULAR THERAPEUTIX, INC | Nayak Sanjay | Officer | SELL | $12.04 | 1,885 | $22,695 | 279,738 |
| 2025-08-28 01:42 | 2025-08-25 | OCUL | OCULAR THERAPEUTIX, INC | Heier Jeffrey S. | Officer | SELL | $12.04 | 3,063 | $36,879 | 259,911 |
| 2025-08-28 01:41 | 2025-08-25 | OCUL | OCULAR THERAPEUTIX, INC | Dugel Pravin | Director, Officer | SELL | $12.04 | 21,494 | $258,788 | 3,227,244 |
| 2025-08-27 23:59 | 2025-08-25 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Mottola Frank | Officer | OPT+S | $44.51 | 14,000 | $623,140 | 15,496 |
| 2025-08-27 23:56 | 2025-08-25 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $45.00 | 1,000 | $45,000 | 1,071,459 |
| 2025-08-28 00:16 | 2025-08-25 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $6.95 | 47,674 | $331,415 | 0 |
| 2025-08-28 03:54 | 2025-08-27 | RCKT | ROCKET PHARMACEUTICALS, INC. | Bjork Elisabeth | Director | BUY | $3.41 | 10,000 | $34,100 | 40,000 |
| 2025-08-27 23:56 | 2025-08-25 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | NEWHALL CHARLES W III | Director | SELL | $45.00 | 1,000 | $45,000 | 133,232 |
| 2025-08-27 00:23 | 2025-08-22 | IONS | IONIS PHARMACEUTICALS INC | Diaz Allene M. | Director | SELL | $42.53 | 1,427 | $60,687 | 18,368 |
| 2025-08-26 23:15 | 2025-08-22 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% owner | SELL | $7.00 | 302,194 | $2,115,358 | 15,456,881 |
| 2025-08-26 23:30 | 2025-08-22 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Officer | OPT+S | $30.43 | 30,000 | $912,900 | 66,270 |
| 2025-08-27 04:40 | 2025-08-22 | WVE | Wave Life Sciences Ltd. | BOLNO PAUL | Director, Officer | SELL | $10.10 | 217,351 | $2,194,810 | 121,000 |
| 2025-08-27 01:01 | 2025-08-22 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Director | SELL | $61.03 | 2,287 | $139,576 | 590,621 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.